PE20220098A1 - Dimero polipeptido con alto contenido en acido sialico, que comprende el dominio extracelular de la subunidad alfa del receptor fc de ige, y composicion farmaceutica que comprende el mismo - Google Patents
Dimero polipeptido con alto contenido en acido sialico, que comprende el dominio extracelular de la subunidad alfa del receptor fc de ige, y composicion farmaceutica que comprende el mismoInfo
- Publication number
- PE20220098A1 PE20220098A1 PE2022000024A PE2022000024A PE20220098A1 PE 20220098 A1 PE20220098 A1 PE 20220098A1 PE 2022000024 A PE2022000024 A PE 2022000024A PE 2022000024 A PE2022000024 A PE 2022000024A PE 20220098 A1 PE20220098 A1 PE 20220098A1
- Authority
- PE
- Peru
- Prior art keywords
- sialic acid
- high content
- ige
- receptor
- present
- Prior art date
Links
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 title abstract 6
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 title abstract 6
- 239000000539 dimer Substances 0.000 title abstract 5
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 102000009109 Fc receptors Human genes 0.000 title abstract 2
- 108010087819 Fc receptors Proteins 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000009490 IgG Receptors Human genes 0.000 abstract 2
- 108010073807 IgG Receptors Proteins 0.000 abstract 2
- 210000003630 histaminocyte Anatomy 0.000 abstract 2
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000036783 anaphylactic response Effects 0.000 abstract 1
- 208000003455 anaphylaxis Diseases 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002688 persistence Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
- 239000013076 target substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invencion se refiere a un receptor Fc de IgE modificado que tiene un alto contenido de acido sialico y una composicion farmaceutica que lo comprende. El dimero polipeptidico que tiene un alto contenido de acido sialico de acuerdo con la presente invencion no solo tiene una excelente seguridad y persistencia en el cuerpo en comparacion con los anticuerpos anti-IgE usados convencionalmente, sino que tambien se une a la IgE muy fuertemente, lo que tiene la ventaja de un ciclo de administracion prolongado. Ademas, el dimero polipeptidico que tiene un alto contenido de acido sialico de acuerdo con la presente invencion es una sustancia diana unica de IgE y, a diferencia de los anticuerpos anti-IgE convencionales a los que se aplica el Fc de IgG1, no se une a un receptor Fc gamma. Por lo tanto, puede inhibir la liberacion de mediadores causada por la union al receptor Fc gamma en la superficie de los mastocitos, de modo que se pueden minimizar los efectos secundarios graves, como la aparicion de anafilaxia, que puede ser causada por la union entre la IgG1 y el receptor Fc gamma III en los mastocitos. Ademas, el dimero polipeptidico que tiene un alto contenido de acido sialico puede mantener una alta concentracion en la sangre incluso en el caso de la administracion subcutanea. Por consiguiente, el dimero polipeptidico que tiene un alto contenido de acido sialico de acuerdo con la presente invencion puede usarse de manera util para la prevencion o el tratamiento de enfermedades alergicas
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190082217 | 2019-07-08 | ||
| PCT/KR2020/008855 WO2021006599A1 (ko) | 2019-07-08 | 2020-07-07 | Ige fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 시알산 함량이 높은 폴리펩티드 이량체 및 이를 포함하는 약학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220098A1 true PE20220098A1 (es) | 2022-01-24 |
Family
ID=74115108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000024A PE20220098A1 (es) | 2019-07-08 | 2020-07-07 | Dimero polipeptido con alto contenido en acido sialico, que comprende el dominio extracelular de la subunidad alfa del receptor fc de ige, y composicion farmaceutica que comprende el mismo |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US12409203B2 (es) |
| EP (1) | EP3998279A4 (es) |
| JP (1) | JP7579815B2 (es) |
| KR (2) | KR102561135B1 (es) |
| CN (2) | CN118580376A (es) |
| AU (1) | AU2020310003B2 (es) |
| BR (1) | BR112022000246A2 (es) |
| CA (1) | CA3145382A1 (es) |
| CL (1) | CL2021003401A1 (es) |
| IL (1) | IL289679B2 (es) |
| MX (1) | MX2022000285A (es) |
| MY (1) | MY208434A (es) |
| PE (1) | PE20220098A1 (es) |
| PH (1) | PH12022550043A1 (es) |
| TW (1) | TWI764191B (es) |
| WO (1) | WO2021006599A1 (es) |
| ZA (1) | ZA202200738B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024509937A (ja) * | 2021-03-09 | 2024-03-05 | ジーアイ・イノベイション・インコーポレイテッド | Ｉｇｅ ｆｃ受容体のアルファサブユニットの細胞外ドメインを含む融合タンパク質の製剤 |
| WO2024136368A1 (ko) * | 2022-12-21 | 2024-06-27 | 건국대학교 산학협력단 | α-2,6-시알산화 면역글로불린의 안구 건조증 또는 염증성 안과 질환의 예방 또는 치료 용도 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3067334A (en) | 1959-03-13 | 1962-12-04 | Garrett Corp | Driving and control means for a plurality of alternators |
| AR008077A1 (es) | 1996-07-26 | 1999-12-09 | Talarico Salinas Laura Beatriz | Un polipeptido de fusion o una sal del mismo, su uso, un proceso para prepararlos, una composicion farmaceutica que los comprende, y un vector. |
| KR100475417B1 (ko) * | 1998-12-30 | 2005-07-18 | 씨제이 주식회사 | 시알산 함량이 높은 재조합 당단백질의 제조방법 |
| EP2043692B1 (en) | 2006-07-25 | 2016-05-18 | Lipoxen Technologies Limited | Polysaccharide derivatives of erythropoietin |
| WO2008028068A2 (en) * | 2006-08-30 | 2008-03-06 | Genentech, Inc. | NON-HUMAN PRIMATE FCεR1α POLYPEPTIDES |
| CN105175553B (zh) * | 2007-05-30 | 2019-11-22 | 浦项工科大学校产学协力团 | 免疫球蛋白融合蛋白 |
| DK2662449T3 (en) | 2007-05-30 | 2017-05-15 | Postech Academy-Industry- Found | immunoglobulin fusion proteins |
| PT2853545T (pt) | 2008-09-17 | 2016-08-26 | Xencor Inc | Anticorpo específico para ige |
| MY182750A (en) * | 2009-10-26 | 2021-02-05 | Genentech Inc | Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis |
| WO2012053828A2 (ko) * | 2010-10-20 | 2012-04-26 | 주식회사 한독약품 | 인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질 |
| US8883134B2 (en) | 2010-10-20 | 2014-11-11 | Handok Pharmaceuticals, Inc. | Human interleukin-1 receptor antagonist—hybrid Fc fusion protein |
| KR20120135865A (ko) * | 2011-06-07 | 2012-12-17 | (주)네오팜 | ＦｃεＲＩ의 수용성 단편을 포함하는 복합체 및 이를 포함하는 ＩｇＥ 매개 알레르기성 질환 치료용 조성물 |
| WO2012169735A2 (ko) | 2011-06-07 | 2012-12-13 | (주)네오팜 | FCεRI의 수용성 단편을 포함하는 복합체 및 이를 포함하는 IGE 매개 알레르기성 질환 치료용 조성물 |
| WO2014144621A2 (en) | 2013-03-15 | 2014-09-18 | Pyranose Biotherapeutics, Inc. | Modified fc fusion proteins |
| KR20150135148A (ko) | 2014-05-23 | 2015-12-02 | 주식회사 제넥신 | Pd-l1 융합 단백질 및 이의 용도 |
| TWI691512B (zh) * | 2015-02-20 | 2020-04-21 | 日商橘生藥品工業股份有限公司 | Ｆｃ融合高親和性ＩｇＥ受體α鏈 |
| CN108093638A (zh) * | 2015-06-11 | 2018-05-29 | 格纳西尼有限公司 | 经修饰的白细胞介素-7蛋白及其用途 |
| KR101847169B1 (ko) * | 2015-10-07 | 2018-04-09 | 주식회사 녹십자 | 지속형 에리트로포이에틴 함유 조성물 |
| US11708399B2 (en) | 2015-12-04 | 2023-07-25 | Genexine, Inc. | Pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein for preventing or treating human papillomavirus-caused diseases |
| EP3192806A1 (en) | 2016-01-13 | 2017-07-19 | Affiris AG | Alpha chain of the high-affinity ige receptor (fceria) |
| JP7128291B2 (ja) | 2018-01-08 | 2022-08-30 | ジーアイ・イノベイション・インコーポレイテッド | ＩｇＥ Ｆｃ受容体のアルファサブユニットの細胞外ドメイン、その物を含む医薬組成物、およびその物を製造する方法 |
| WO2019135666A1 (ko) | 2018-01-08 | 2019-07-11 | 주식회사 프로젠 | Ige fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 약학적 조성물 |
| SG11202005863TA (en) | 2018-01-12 | 2020-07-29 | Gi Innovation Inc | Composition comprising probiotics and polypeptide having binding affinity for ige and use thereof |
-
2020
- 2020-07-07 JP JP2021575270A patent/JP7579815B2/ja active Active
- 2020-07-07 CA CA3145382A patent/CA3145382A1/en active Pending
- 2020-07-07 KR KR1020200083486A patent/KR102561135B1/ko active Active
- 2020-07-07 PE PE2022000024A patent/PE20220098A1/es unknown
- 2020-07-07 CN CN202410837315.5A patent/CN118580376A/zh active Pending
- 2020-07-07 BR BR112022000246A patent/BR112022000246A2/pt unknown
- 2020-07-07 CN CN202080049890.9A patent/CN114080398B/zh active Active
- 2020-07-07 US US17/625,668 patent/US12409203B2/en active Active
- 2020-07-07 EP EP20837726.7A patent/EP3998279A4/en active Pending
- 2020-07-07 MY MYPI2021007574A patent/MY208434A/en unknown
- 2020-07-07 AU AU2020310003A patent/AU2020310003B2/en active Active
- 2020-07-07 WO PCT/KR2020/008855 patent/WO2021006599A1/ko not_active Ceased
- 2020-07-07 PH PH1/2022/550043A patent/PH12022550043A1/en unknown
- 2020-07-07 IL IL289679A patent/IL289679B2/en unknown
- 2020-07-07 MX MX2022000285A patent/MX2022000285A/es unknown
- 2020-07-08 TW TW109123074A patent/TWI764191B/zh active
-
2021
- 2021-12-17 CL CL2021003401A patent/CL2021003401A1/es unknown
-
2022
- 2022-01-14 ZA ZA2022/00738A patent/ZA202200738B/en unknown
-
2023
- 2023-07-24 KR KR1020230096002A patent/KR20230115283A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA3145382A1 (en) | 2021-01-14 |
| BR112022000246A2 (pt) | 2022-02-22 |
| MX2022000285A (es) | 2022-02-03 |
| WO2021006599A1 (ko) | 2021-01-14 |
| TW202116799A (zh) | 2021-05-01 |
| CN114080398B (zh) | 2024-05-31 |
| CN118580376A (zh) | 2024-09-03 |
| JP7579815B2 (ja) | 2024-11-08 |
| AU2020310003A1 (en) | 2022-01-06 |
| IL289679B1 (en) | 2025-01-01 |
| KR20210006293A (ko) | 2021-01-18 |
| US20220257693A1 (en) | 2022-08-18 |
| KR102561135B1 (ko) | 2023-07-31 |
| CN114080398A (zh) | 2022-02-22 |
| ZA202200738B (en) | 2023-11-29 |
| JP2022539684A (ja) | 2022-09-13 |
| US12409203B2 (en) | 2025-09-09 |
| MY208434A (en) | 2025-05-08 |
| CL2021003401A1 (es) | 2022-10-14 |
| IL289679B2 (en) | 2025-05-01 |
| IL289679A (en) | 2022-03-01 |
| TWI764191B (zh) | 2022-05-11 |
| PH12022550043A1 (en) | 2023-02-27 |
| EP3998279A1 (en) | 2022-05-18 |
| AU2020310003B2 (en) | 2025-12-18 |
| EP3998279A4 (en) | 2023-01-18 |
| KR20230115283A (ko) | 2023-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211202A1 (es) | Composiciones de glp-1 y sus usos | |
| PE20220098A1 (es) | Dimero polipeptido con alto contenido en acido sialico, que comprende el dominio extracelular de la subunidad alfa del receptor fc de ige, y composicion farmaceutica que comprende el mismo | |
| BR112022007380A2 (pt) | Composto bifuncional, e, composição | |
| Kashir et al. | Phospholipase C zeta and calcium oscillations at fertilisation: the evidence, applications, and further questions | |
| CL2020001798A1 (es) | Dominio extracelular de una subunidad alfa del receptor fc para ige, composición farmacéutica que lo comprende y método para su producción. | |
| PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
| ECSP19003047A (es) | Nuevos análogos de urocortina-2 modificados con ácido graso para el tratamiento de diabetes y enfermedad renal crónica | |
| AR080663A1 (es) | Proteinas de union especificas y sus usos | |
| BR112014029099A2 (pt) | anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende | |
| PE20121541A1 (es) | Antigenos de virus de sincicio respiratorio recombinantes | |
| BR112018075396A2 (pt) | anticorpo neutralizante contra dengue para uso em um método de prevenção e/ou tratamento de infecção por zika | |
| BR112023023559A2 (pt) | Moduladores de receptores acoplados à proteína g | |
| PE20191836A1 (es) | Compuesto de insulina acilada | |
| MX9204703A (es) | Acidos n-acil-n-heterociclilalquilamino, proceso para su obtencion y composicion farmaceutica que los contiene. | |
| BR112018075222A2 (pt) | anticorpos anti-tnfrsf25 | |
| BR112022008201A2 (pt) | Degradação de proteínas de superfície usando agente de ligação biespecífico | |
| BR112022001255A2 (pt) | Métodos de tratamento de distúrbios mediados por anticorpos com antagonistas de fcrn | |
| MX2023002087A (es) | Agonistas del receptor crf2 y su uso en terapia. | |
| BR112013032088A2 (pt) | "polipeptídeo, composição farmacêutica e seu uso" | |
| BR112022013204A2 (pt) | Usos de uma composição e de uma preparação combinada | |
| PE20210123A1 (es) | Compuesto de anillo de metillactama y uso farmaceutico del mismo | |
| CO2020001322A2 (es) | Tratamiento de hemorragia gastrointestinal en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante | |
| BR112015017909A2 (pt) | redução do risco de doença autoimune | |
| Ratnayake et al. | Acute myocardial injury after scorpion (Hottentotta tamulus) sting | |
| PE20121553A1 (es) | Uso de una fuente de l3 y/o l5 como vacuna o como diagnostico para una efermedad parasitaria |